You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC / CE

The New Side of Incretin-Based Therapy in Type 2 Diabetes: Exploring Advances From EASD 2021

  • Authors: Carol Wysham, MD; Stefano Del Prato, MD; Juan Pablo Frias, MD
  • CME / ABIM MOC / CE Released: 3/15/2022
  • Valid for credit through: 3/15/2023
Start Activity

  • Credits Available

    Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.50 ABIM MOC points

    Nurses - 0.50 ANCC Contact Hour(s) (0.5 contact hours are in the area of pharmacology)

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This educational activity is intended for an international audience of diabetologists/endocrinologists, primary care physicians, nurses and other healthcare professionals who care for individuals with type 2 diabetes (T2D). 

The goal of this activity for primary care providers (PCPs) is to improve the knowledge and awareness of emerging dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapies and their mechanism of action, the clinical data on their glycemic and extra-glycemic effects, particularly on weight loss, and their potential effectiveness/benefits in T2D management as they progress through development.

The goal of this activity for diabetologists/endocrinologists is to increase clinical understanding of emerging dual GIP and GLP-1 RA therapies and implications of clinical data on their glycemic and extra-glycemic effects, particularly on weight loss, and improve clinical appreciation of how these agents may potentially fit into T2D management as they progress through development.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Mechanism of glucose control, weight loss, and lipid metabolism of emerging dual GIP and GLP-1 RA therapies  
    • Clinical trial data from the European Association for the Study of Diabetes (EASD) 2021 for emerging dual GIP and GLP-1 RA therapies for T2D management  
    • Role of emerging dual GIP and GLP-1 RA therapies in clinical management of T2D 


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Medscape policies. Others involved in the planning of this activity have no relevant financial relationships.


Moderator

  • Carol Wysham, MD

    Clinical Professor of Medicine
    University of Washington School of Medicine
    Rockwood/MultiCare Center for Diabetes and Endocrinology
    Spokane, Washington
    United States

    Disclosures

    Disclosure: Carol Wysham, MD, has the following relevant financial relationships:
    Advisor or consultant for: Abbott; Novo Nordisk; Sanofi
    Speaker or a member of a speakers bureau for: Astra Zeneca; Boehringher Ingelheim; Eli Lilly; Janssen; Novo Nordisk; Sanofi
    Grants for clinical research from: Abbott; Gilead; Corcept; Novo Nordisk; Mylan; Eli Lilly

Panelists

  • Stefano Del Prato, MD

    Professor of Endocrinology and Metabolism
    University of Pisa School of Medicine
    Chief, Section of Diabetes
    University of Pisa, Italy
    Pisa, Italy

    Disclosures

    Disclosure: Stefano Del Prato, MD, has the following relevant financial relationships:
    Advisor or consultant for: Applied Therapeutics; AstraZeneca; Boehringer Ingelheim; Eli Lilly and Co; Merck & Co.; Novartis Pharmaceuticals; Novo Nordisk; Sanofi
    Speaker or a member of a speakers bureau for: AstraZeneca; Boehringer Ingelheim; Eli Lilly and Co; Merck & Co.; Novartis Pharmaceuticals; Novo Nordisk; Sanofi; Takeda Pharmaceuticals
    Grants for clinical research from: AstraZeneca; Boehringer Ingelheim

  • Juan Pablo Frias, MD

    Medical Director and Principal Investigator
    Velocity Clinical Research
    Los Angeles, California
    United States

    Disclosures

    Disclosure: Juan Pablo Frias, MD, has the following relevant financial relationships:
    Advisor or consultant for: Akero; Altimmune; Axcella Health; Boehringer Ingelheim; Carmot; Coherus Therapeutics; Echosens; 89bio; Eli Lilly; Gilead; Intercept; Merck; Novo Nordisk; Pfizer; Sanofi
    Speaker or a member of a speakers bureau for: Eli Lilly; Merck; Sanofi
    Grants for clinical research from: Akero; AbbVie; AstraZeneca; Boehringer Ingelheim; BMS; Eli Lilly; Intercept; Janssen; Madrigal; Metacrine; Merck; NorthSea Therapeutics; Novartis; Novo Nordisk; Oramed; Pfizer; Poxil; Sanofi; Theracos

Editor

  • Anne G. Le, PharmD

    Senior Medical Education Director, Medscape, LLC

    Disclosures

    Disclosure: Anne G. Le, PharmD, has disclosed no relevant financial relationships.

Compliance Reviewer/Nurse Planner

  • Stephanie Corder, ND, RN, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Disclosure: Stephanie Corder, ND, RN, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

    For Nurses

  • Awarded 0.50 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.50 contact hours are in the area of pharmacology.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

The New Side of Incretin-Based Therapy in Type 2 Diabetes: Exploring Advances From EASD 2021

Authors: Carol Wysham, MD; Stefano Del Prato, MD; Juan Pablo Frias, MDFaculty and Disclosures

CME / ABIM MOC / CE Released: 3/15/2022

Valid for credit through: 3/15/2023

processing....

Educational Impact Challenge

The goal of this activity for primary care providers (PCPs) is to improve the knowledge and awareness of emerging dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapies and their mechanism of action, the clinical data on their glycemic and extra-glycemic effects, particularly on weight loss, and their potential effectiveness/benefits in T2D management as they progress through development.

The goal of this activity for diabetologists/endocrinologists is to increase clinical understanding of emerging dual GIP and GLP-1 RA therapies and implications of clinical data on their glycemic and extra-glycemic effects, particularly on weight loss, and improve clinical appreciation of how these agents may potentially fit into T2D management as they progress through development.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.